Trilaciclib

Drug Profile

Trilaciclib

Alternative Names: G1T 28; G1T28-1

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Chemoprotectants; Radioprotectives; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Small cell lung cancer
  • Phase I Cancer; Myelosuppression

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Breast cancer (Combination therapy, Metastatic disease) in USA (IV) (NCT02978716)
  • 05 Dec 2016 G1 Therapeutics and Genentech plan a phase II trial for Small-cell lung cancer
  • 28 Nov 2016 G1 Therapeutics plans a phase II trial for Breast cancer (Metastatic disease, Combination therapy) in USA (IV) (NCT02978716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top